Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 6/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585436 | 0.88 | MRGPRX4 (0.49) | MRGPRX4TP53PKMHDAC4HDAC6 | |
| SCHEMBL5340854 | 0.88 | LMNA (0.45) | MRGPRX4PTGER2PTGDRPTGER3HDAC4 | |
| SCHEMBL6979862 | 0.85 | TP53 (0.40) | MRGPRX4TP53PKMLIG1PTGER2 | |
| SCHEMBL163740 | 0.81 | MAPT (0.40) | BACE1HPGDL3MBTL1MAPTALDH1A1 | |
| SCHEMBL3147053 | 0.79 | BACE1 (0.34) | MRGPRX4HDAC4HDAC6BACE1 | |
| SCHEMBL3314628 | 0.78 | MRGPRX4 (0.45) | MRGPRX4TP53PKMLIG1PTGER2 | |
| SCHEMBL3147047 | 0.78 | F2 (0.32) | HPGDATMALDH1A1 | |
| SCHEMBL5343981 | 0.78 | — | — | |
| SCHEMBL3128598 | 0.78 | F2 (0.32) | HPGDATMALDH1A1 | |
| SCHEMBL22572473 | 0.77 | ADRA2C (0.40) | BACE1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| EP-2019827-A1 | INTEGRASE INHIBITORS 3 | Avexa Limited (AU) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007124546-A1 | INTEGRASE INHIBITORS 3 | AVEXA LIMITED (AU) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009973-A1 | Integrase Inhibitors 3 | TYMP, IMPDH1, IMPDH2 | MRGPRX4 3732/4885TP53 1213/4885PKM 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.